Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens

Fig. 2

Comparison of ER, PR, Ki-67, and HER2 status according to IHC (ER, PR and Ki-67 considered to be positive with ≥1%, ≥1, and 20% immunostaining respectively, HercepTest scored 2+ (with confirmed HER2 amplification using SISH testing) or 3+ considered to be HER2-positive) and STRAT4 (ER, PR, Ki-67, and HER2 considered to be positive with dCt cut offs ≥ − 1.0, ≥ − 3.5, ≥ − 4.0 and ≥ − 1.0 respectively) in the core biopsies

Back to article page